Drug Profile
ALX 0625
Latest Information Update: 12 Dec 2002
Price :
$50
*
At a glance
- Originator NPS Allelix
- Class Antimigraines
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Migraine
Most Recent Events
- 12 Dec 2002 Discontinued - Preclinical for Migraine in Canada (unspecified route)
- 10 Feb 2000 Allelix Biopharmaceuticals has merged with NPS Pharmaceuticals
- 19 Mar 1997 Preclinical development for Migraine in Canada (Unknown route)